Cat. #156470

CCRF-CEM-R5 Cell line

Name: CCRF-CEM-R5 Cell line
SKU: 156470
Availability: InStock

Cat. #: 156470

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 8-10 weeks

Organism: Human

Tissue: Bone Marrow

Disease: Cancer

Model: Tumour line

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Enquire or request a quote

Contributor

Inventor: Aintzane Asumendi ; Aintzane Apraiz ; Dolores Boyano

Institute: University of the Basque Country (EHU)

Tool Details

Target Details

Handling

References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

Name: CCRF-CEM-R5 Cell line
Cancer type: Blood cancer
Cancers detailed: Acute Lymphoblastic Leukemia;Cancer
Research fields: Cancer;Drug development
Tool sub type: Continuous
Parental cell: CCRF-CEM
Organism: Human
Tissue: Bone Marrow
Disease: Cancer
Growth properties: Suspension
Model: Tumour line
Conditional: No
Description: CCRF-CEM-R5 cell line is resistant to 4-HPR, a synthetic retinoid with potent pro-apoptotic activity against several types of cancer, including leukemia cells.
Production details: CCRF-CEM-R5 cell line, resistant to up to 5 mM of 4-HPR, was obtained by gradual selection. Parental CCRF-CEM cells were continuously exposed to increasing 4-HPR concentrations, starting from 0.5 mM.
Recommended controls: Control cells are CCRF-CEM parental cells that are sensitive to higher than 1mM 4HPR

Target Details

Target: Relevant disease (Acute Lymphoblastic Leukemia/ALL); Drug (synthetic retinoid 4-HPR: fenretinide or N-(4-hydroxyphenyl)retinamide)

Handling

Format: Frozen
Growth medium: Cells should be grown in RPMI 1640 with 2mM L-glutamine supplemented with 10% heat inactivated FBS. Keep at 37?Â°C in a humidified incubator containing 5% CO2. In order to preserve their resistant intermitent exposures to 5mM 4-HPR is recomended. 4-HPR removal from R5 cell culture for up to 8 passages or 3 weeks has not shown any decrease on drug resistance although it does affect endogenous sphingolipid profile (specified in the reference paper).
Unit size: 1x10^6 cells / vial
Shipping conditions: Dry ice

References

Apraiz et al. 2011. BMC Cancer. 11:477. PMID: 22061047.